The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Items 201–300 of 1,002
Wilson, E. N., Carmo, S. D., Welikovitch, L. A., Hall, H., Aguilar, L. F., Foret, M. K., Iulita, M. F., Jia, D. T., Marks, A. R., Allard, S. T. M., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190862 · Cited by 53
Self-citationMartins, M. M., Branco, P. S., & Ferreira, L. M. (2023) · ChemistrySelect · doi:10.1002/slct.202300461 · Cited by 53
Barber, K., Mendonca, P., & Soliman, K. F. A. (2023) · Brain Sciences · doi:10.3390/brainsci13010145 · Cited by 53
Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer’s Disease
Vrabec, R., Blunden, G., & Cahlíková, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054399 · Cited by 53
Silva, R. O., Counil, H., Rabanel, J., Haddad, M., Zaouter, C., Khedher, M. R. B., Patten, S. A., & Ramassamy, C. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s449227 · Cited by 53
Silva, S. S. L., Tureck, L. V., Souza, L. C., Mello-Hortega, J. V., Piumbini, A. L., Teixeira, M. D., Alle, L. F., Vital, M. A. B. F., & de Souza, R. L. R. (2022) · Brain Research · doi:10.1016/j.brainres.2022.148175 · Cited by 53
Rawa, M. S. A., Mazlan, M. K. N., Ahmad, R., Nogawa, T., & Wahab, H. A. (2022) · Plants · doi:10.3390/plants11111476 · Cited by 53
The role of the locus coeruleus in shaping adaptive cortical melodies
Wainstein, G., Müller, E. J., Taylor, N. L., Munn, B., & Shine, J. M. (2022) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2022.03.006 · Cited by 55
Liu, X., Naomi, S. S. M., Sharon, W. L., & Russell, E. J. (2021) · Aging and disease · doi:10.14336/ad.2021.0510 · Cited by 52
Mangiatordi, G. F., Intranuovo, F., Delre, P., Abatematteo, F. S., Abate, C., Niso, M., Creanza, T. M., Ancona, N., Stefanachi, A., & Contino, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01357 · Cited by 52
Pavlov, V. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107794 · Cited by 52
Ni, H., Liu, M., Cao, M., Zhang, L., Zhao, Y., Yi, L., Li, Y., Liu, L., Wang, P., Du, Q., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116190 · Cited by 53
Neuroprotective effect of phytoconstituents via nanotechnology for treatment of Alzheimer diseases
Paramanick, D., Singh, V. D., & Singh, V. K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.058 · Cited by 51
Sultzer, D. L., Lim, A. C., Gordon, H. L., Yarns, B. C., & Melrose, R. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00954-w · Cited by 51
Wang, Z., Lian, W., He, J., He, X.-L., Wang, Y., Pan, C., Li, M., Zhang, W., Liu, L.-Q., & Xu, J. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115252 · Cited by 51
How reliable is cerebral blood flow to map changes in neuronal activity?
Lecrux, C., Bourourou, M., & Hamel, E. (2019) · Autonomic Neuroscience · doi:10.1016/j.autneu.2019.01.005 · Cited by 50
Lista, S., Vergallo, A., Teipel, S. J., Lemercier, P., Giorgi, F. S., Gabelle, A., Garaci, F., Mercuri, N. B., Babiloni, C., Gaire, B. P., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101819 · Cited by 50
Self-citationNanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis
Li, L., He, R., Yan, H., Leng, Z., Zhu, S., & Gu, Z. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101654 · Cited by 50
Slater, C. L., & Wang, Q. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.397 · Cited by 50
Crews, F. T., Fisher, R., Deason, C., & Vetreno, R. P. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.652494 · Cited by 50
Zhu, Q., Zhang, N., Hu, N., Jiang, R., Lu, H., Xuan, A., Long, D., & Chen, Y. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10918 · Cited by 50
Moss, D. E., & Perez, R. G. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211215150547 · Cited by 51
Fronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 49
Nanomedicines in the Management of Alzheimer’s Disease: Current View and Future Prospects
Chopra, H., Bibi, S., Singh, I., Kamal, M. A., Islam, F., Alhumaydhi, F. A., Emran, T. B., & Cavalu, S. D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879114 · Cited by 49
Liu, Y., Uras, G., Onuwaje, I., Li, W., Yao, H., Xu, S., Li, X., Li, X., Phillips, J. B., Allen, S., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114305 · Cited by 49
Alzheimer’s Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review
Knorz, A. L., & Quante, A. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211044746 · Cited by 50
The role of nicotinic cholinergic neurotransmission in delusional thinking
Caton, M., Ochoa, E. L. M., & Barrantes, F. J. (2020) · Schizophrenia · doi:10.1038/s41537-020-0105-9 · Cited by 49
Topal, F., Ertaş, B., Güler, E., Gurbuz, F., Ozcan, G. S., Aydemir, O., Böcekçı, V. G., Duruksu, G., Cam, C. S., Yazır, Y., et al. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.212870 · Cited by 49
Surya, K., Manickam, N., Jayachandran, K. S., Kandasamy, M., & Anusuyadevi, M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220559 · Cited by 49
Animal models of Alzheimer’s disease: Current strategies and new directions
Qing, W., Zhu, B. T., Bai-Ting, Z., & Peng, L. (2024) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2024.274 · Cited by 49
Argueti-Ostrovsky, S., Alfahel, L., Kahn, J., & Israelson, A. (2021) · Cells · doi:10.3390/cells10092438 · Cited by 48
8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases
Knez, D., Diez‐Iriepa, D., Chioua, M., Gottinger, A., Denic, M., Chantegreil, F., Nachon, F., Brazzolotto, X., Skrzypczak-Wiercioch, A., Meden, A., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.013 · Cited by 48
Spies, C., Knaak, C., Mertens, M., Brockhaus, W., Shadenok, A., Wiebach, J., Kunzmann, K., Feldheiser, A., Pratschke, J., Müller, O., et al. (2021) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001456 · Cited by 48
Fiore, A., Preziosa, P., Tedone, N., Margoni, M., Vizzino, C., Mistri, D., Gueye, M., Rocca, M. A., & Filippi, M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01943-1 · Cited by 48
Stanciu, G. D., Rusu, R. N., Bild, V., Filipiuc, L. E., Tamba, B.-I., & Ababei, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9050576 · Cited by 47
“Figure 1 highlights some of the most studied hypotheses for AD, including Aβ aggregation [10–12], cholinergic dysfunction [13,14], tau aggregation [15,16], oxidative stress [17,18], inflammation [19–21].”
BackgroundVicente-Zurdo, D., Rosales-Conrado, N., León-González, M. E., Brunetti, L., Piemontese, L., Pereira-Santos, A. R., Cardoso, S. M., Madrid, Y., Chaves, S., & Santos, M. A. (2022) · Biomedicines · doi:10.3390/biomedicines10071510 · Cited by 47
“For this reason, inhibitors of cholinesterases (acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)) increase the availability of ACh and BCh (involved in cholinergic signalling), thus improving central nervous system (CNS) performance and leading to symptomatic relief [3,26].”
BackgroundEngels, N., Koops, E. A., Prokopiou, P. C., Egroo, M. V., Schneider, C., Riphagen, J. M., Singhal, T., & Jacobs, H. I. L. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104998 · Cited by 48
Association between anticholinergic burden and dementia in UK Biobank
Mur, J., Russ, T. C., Cox, S. R., Marioni, R. E., & Terrera, G. M. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12290 · Cited by 47
Structural (dys)connectivity associates with cholinergic cell density in Alzheimer’s disease
Lin, C., Frigerio, I., Boon, B. D. C., Zhou, Z., Rozemüller, A. J. M., Bouwman, F. H., Schoonheim, M. M., van de Berg, W. D. J., & Jonkman, L. E. (2022) · Brain · doi:10.1093/brain/awac093 · Cited by 47
Contribution of astrocytes to metabolic dysfunction in the Alzheimer’s disease brain
Zulfiqar, S., Garg, P., & Nieweg, K. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0140 · Cited by 47
Li, J., Du, Q., Li, N., Du, S., & Sun, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111167 · Cited by 47
Baviskar, P. S., & Mahajan, H. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102990 · Cited by 47
Hu, W., Song, M., Wang, C., Guo, Z., Li, Y., & Wang, D. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.117 · Cited by 47
Mesenchymal and Neural Stem Cell-Derived Exosomes in Treating Alzheimer’s Disease
Wang, H., Huber, C. C., & Li, X. (2023) · Bioengineering · doi:10.3390/bioengineering10020253 · Cited by 46
Neuroinflammation of Microglial Regulation in Alzheimer’s Disease: Therapeutic Approaches
Chen, H., Zeng, Y., Wang, D., Li, Y., Xing, J., Zeng, Y., Liu, Z., Zhou, X., & Fan, H. J. (2024) · Molecules · doi:10.3390/molecules29071478 · Cited by 46
Stem Cell Therapies in Alzheimer’s Disease: Applications for Disease Modeling
Si, Z., & Wang, X. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000324 · Cited by 46
Systems Pharmacology Approach to Investigate the Mechanism of Kai-Xin-San in Alzheimer’s Disease
Luo, Y., Li, D., Liao, Y., Cai, C., Wu, Q., Ke, H., Liu, X., Li, H.-L., Hong, H., Xu, Y., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00381 · Cited by 47
Prabha, S., Sajad, M., Hasan, G. M., Islam, A., Hassan, M. I., & Thakur, S. C. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102476 · Cited by 46
Xia, Y., Eeles, E. M., Fripp, J., Pinsker, D. M., Thomas, P. A., Latter, M. J., Doré, V., Fazlollahi, A., Bourgeat, P., Villemagne, V. L., et al. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.102992 · Cited by 46
Guan, W., & Wang, Q. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154938 · Cited by 46
Dynamic regulation of the cholinergic system in the spinal central nervous system
Rima, M., Lattouf, Y., Younes, M. A., Bullier, E., Legendre, P., Mangin, J., & Hong, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-72524-3 · Cited by 46
MicroRNA-195 liposomes for therapy of Alzheimer's disease
Su, D., Chen, Z., An, X., Yang, J., Yang, J., Wang, X., Qu, Y., Chen, G., Chai, Y.-N., Liu, X., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.003 · Cited by 46
Therapeutic potential of neurogenesis and melatonin regulation in Alzheimer's disease
Mihardja, M., Roy, J., Wong, K. Y., Aquili, L., Heng, B. C., Chan, Y., Fung, M., & Lim, L. W. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14436 · Cited by 45
Mamun, A. A., Maříková, J., Hulcová, D., Janoušek, J., Šafratová, M., Nováková, L., Kučera, T., Hrabinová, M., Kuneš, J., Korábečný, J., et al. (2020) · Biomolecules · doi:10.3390/biom10050800 · Cited by 45
George, N., Akhtar, M. J., Balushi, K. A. A., & Khan, S. A. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105941 · Cited by 45
Carotenuto, A., Wilson, H., Giordano, B., Caminiti, S. P., Chappell, Z., Williams, S., Hammers, A., Silber, E., Brex, P., & Politis, M. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09806-3 · Cited by 45
Joseph, E., Villalobos-Acosta, D. M. Á., Torres-Ramos, M., Farfán‐García, E. D., Gómez‐López, M., Miliar-García, Á., Fragoso-Vázquez, M. J., García-Marín, I. D., Correa‐Basurto, J., & Rosales‐Hernández, M. C. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01426-5 · Cited by 44
Costanzo, M., Cutrona, C., Leodori, G., Malimpensa, L., D’Antonio, F., Conte, A., & Belvisi, D. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01607-4 · Cited by 44
Animal models of Alzheimer’s disease: preclinical insights and challenges
Xu, Q., Yang, W., Zhong, M., Lin, Z., Gray, N. E., & Xian, Y. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0001 · Cited by 45
Baumel, B. S., Doraiswamy, P. M., Sabbagh, M. N., & Wurtman, R. J. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00227-y · Cited by 44
Therapeutic approaches for improving cognitive function in the aging brain
Chen, L., Jiao, J., & Zhang, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1060556 · Cited by 44
Gür, E., Fertan, E., Kosel, F., Wong, A. A., Balcı, F., & Brown, R. E. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.11.047 · Cited by 44
Ailioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 44
Chen, R., Li, X., Chen, H., Wang, K., Xue, T., Mi, J., Ban, Y., Zhu, G., Zhou, Y. M., Dong, W., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115253 · Cited by 44
Atrophy of specific amygdala subfields in subjects converting to mild cognitive impairment
Padulo, C., Sestieri, C., Punzi, M., Picerni, E., Chiacchiaretta, P., Tullo, M. G., Granzotto, A., Baldassarre, A., ONOFRJ, M. C., Ferretti, A., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12436 · Cited by 44
Endothelial Progenitor Cells and Vascular Alterations in Alzheimer’s Disease
Custodia, A., Ouro, A., Romaus-Sanjurjo, D., Pías-Peleteiro, J. M., de Vries, H. E., Castillo, J., & Sobrino, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.811210 · Cited by 43
Bajda, M., Łażewska, D., Godyń, J., Zaręba, P., Kuder, K., Hagenow, S., Łątka, K., Stawarska, E., Stark, H., Kieć‐Kononowicz, K., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111785 · Cited by 43
Gut-Brain Axis and Neurological Disorders-How Microbiomes Affect our Mental Health
Bhatia, N. Y., Jalgaonkar, M. P., Hargude, A. B., Sherje, A. P., Oza, M. J., & Doshi, G. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220822172039 · Cited by 43
Dhami, M., Aran, K. R., & Singh, S. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211118144602 · Cited by 43
Hu, Y. R., Xing, S. L., Chen, C., Shen, D. Z., & Chen, J. L. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210608103831 · Cited by 43
Kohelová, E., Maříková, J., Korábečný, J., Hulcová, D., Kučera, T., Jun, D., Chlebek, J., Jenčo, J., Šafratová, M., Hrabinová, M., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104567 · Cited by 43
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 43
Chiesa, P. A., Cavedo, E., Grothe, M. J., Houot, M., Teipel, S. J., Potier, M.-C., Habert, M.-O., Lista, S., Dubois, B., Hampel, H., et al. (2019) · Radiology · doi:10.1148/radiol.2018180268 · Cited by 42
Self-citationAborode, A. T., Emmanuel, O. A., Onifade, I. A., Olotu, E., Otorkpa, O. J., Mehmood, M. Q., Abdulai, S. I., Jamiu, A. T., Osinuga, A., Oko, C. I., et al. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2024.100034 · Cited by 43
Trace Detection of Hydrogen Peroxide via Dynamic Double Emulsions
Fong, D., & Swager, T. M. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00683 · Cited by 42
Neuropharmacology of Organoselenium Compounds in Mental Disorders and Degenerative Diseases
Birmann, P. T., Casaril, A. M., Abenante, L., Penteado, F., Brüning, C. A., Savegnago, L., & Lenardao, E. J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220615124412 · Cited by 42
Recent Developments in Coumarin Derivatives as Neuroprotective Agents
Mishra, P. S., Kumar, A., Kaur, K., & Jaitak, V. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230714160047 · Cited by 42
Vastegani, S. M., Khoshnam, S. E., Mansouri, E., Hajipour, S., Ghafouri, S., Bakhtiari, N., Sarkaki, A., & Farbood, Y. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114100 · Cited by 42
Mezeiová, E., Janočková, J., Andrýs, R., Soukup, O., Kobrlová, T., Múčková, Ľ., Pejchal, J., Šimunková, M. M., Handl, J., Micankova, P., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113112 · Cited by 42
Uncharted Source of Medicinal Products: The Case of the Hedychium Genus
Tavares, W. R., Barreto, M. D. C., & Seca, A. M. L. (2020) · Medicines · doi:10.3390/medicines7050023 · Cited by 42
Rowan, M. T., Alharthi, A. A., Noel-Storr, A. H., Myint, P. K., Stewart, C., McCleery, J. M., & Quinn, T. J. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015405.pub2 · Cited by 41
An Update on the Routes for the Delivery of Donepezil
Zhao, Z. Q., Chen, B. Z., Zhang, X. P., Zheng, H., & Guo, X. D. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00290 · Cited by 41
Punzi, M., Sestieri, C., Picerni, E., Chiarelli, A. M., Padulo, C., Pizzi, A. D., Tullo, M. G., Tosoni, A., Granzotto, A., Penna, S. D., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27429 · Cited by 41
Pharmacological Modulators of Tau Aggregation and Spreading
Dominguez‐Meijide, A., Vasili, E., & Outeiro, T. F. (2020) · Brain Sciences · doi:10.3390/brainsci10110858 · Cited by 42
Colizzi, M., Bortoletto, R., Colli, C., Bonomo, E., Pagliaro, D., Maso, E., Gennaro, G. D., & Balestrieri, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1038122 · Cited by 41
Fronza, M. G., Baldinotti, R., Fetter, J., Rosa, S. G., Sacramento, M., Nogueira, C. W., Alves, D. A. C., Praticò, D., & Savegnago, L. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.10.002 · Cited by 42
Cahlíková, L., Vrabec, R., Pidaný, F., Peřinová, R., Maafi, N., Mamun, A. A., Ritomská, A., Wijaya, V., & Blunden, G. (2021) · Molecules · doi:10.3390/molecules26175240 · Cited by 41
Boukholda, K., Gargouri, B., Aouey, B., Attaai, A., Elkodous, M. A., Najimi, M., Fiebich, B. L., Bouchard, M., & Fetoui, H. (2021) · NanoImpact · doi:10.1016/j.impact.2021.100358 · Cited by 41
Shulman, D., Dubnov, S., Zorbaz, T., Madrer, N., Paldor, I., Bennett, D. A., Seshadri, S. S., Mufson, E. J., Greenberg, D., Loewenstein, Y., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13095 · Cited by 41
Li, Q., Wang, Q., Guan, H., Zhou, Y., & Liu, L. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s279147 · Cited by 42
MiR-29c-3p May Promote the Progression of Alzheimer’s Disease through BACE1
Cao, Y., Tan, X., Lu, Q., Huang, K., Tang, X.-E., & He, Z. (2021) · Journal of Healthcare Engineering · doi:10.1155/2021/2031407 · Cited by 40
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 41
Pentz, R., Iulita, M. F., Ducatenzeiler, A., Videla, L., Benejam, B., Carmona‐Iragui, M., Blesa, R., Lleó, A., Fortea, J., & Cuello, A. C. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12229 · Cited by 40
Self-citationDobric, A., Luca, S. N. D., Spencer, S. J., Bozinovski, S., Saling, M. M., McDonald, C. F., & Vlahos, R. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108017 · Cited by 40
Iqbal, D., Khan, M. S., Waiz, M., Rehman, M. T., Alaidarous, M., Jamal, A., Alothaim, A. S., Alajmi, M. F., Alshehri, B., Banawas, S., et al. (2021) · Cells · doi:10.3390/cells10123533 · Cited by 40
Research progress of PROTACs for neurodegenerative diseases therapy
Cai, Z., Yang, Z., Li, H., & Fang, Y. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107386 · Cited by 40
Cacabelos, R., Martínez-Iglesias, O. A., Cacabelos, N., Carrera, I., Corzo, L., & Naidoo, V. (2024) · Life · doi:10.3390/life14121555 · Cited by 40
Lee, D., Shen, A. M., Garbuzenko, O. B., & Minko, T. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00967-x · Cited by 40
Yekeler, H. B., Güler, E., Beato, P. S., Priya, S., Abobakr, F. K. M., Doğan, M., Üner, B., Kalaskar, D. M., & Çam, M. E. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131841 · Cited by 40
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.